168 related articles for article (PubMed ID: 32000215)
21. The role of gene fusions in melanocytic neoplasms.
Quan VL; Panah E; Zhang B; Shi K; Mohan LS; Gerami P
J Cutan Pathol; 2019 Nov; 46(11):878-887. PubMed ID: 31152596
[TBL] [Abstract][Full Text] [Related]
22. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
23. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations.
Emley A; Yang S; Wajapeyee N; Green MR; Mahalingam M
J Cutan Pathol; 2010 Mar; 37(3):344-9. PubMed ID: 19788444
[TBL] [Abstract][Full Text] [Related]
25. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
[TBL] [Abstract][Full Text] [Related]
26. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions.
Saraggi D; Salmaso R; Zamuner C; Munari G; Lanza C; Alaibac MS; Bassetto F; Rugge M; Montesco MC; Cerroni L; Fassan M
J Am Acad Dermatol; 2018 Oct; 79(4):728-735. PubMed ID: 29920315
[TBL] [Abstract][Full Text] [Related]
28. Combined utility of p16 and BRAF V600E in the evaluation of spitzoid tumors: Superiority to PRAME and correlation with FISH.
McAfee JL; Scarborough R; Jia XS; Azzato EM; Astbury C; Ronen S; Andea AA; Billings SD; Ko JS
J Cutan Pathol; 2023 Feb; 50(2):155-168. PubMed ID: 36261329
[TBL] [Abstract][Full Text] [Related]
29. A Series of RET Fusion Spitz Neoplasms With Plaque-Like Silhouette and Dyscohesive Nesting of Epithelioid Melanocytes.
Kim D; Compres EV; Zhang B; Khan AU; Sunshine JC; Quan VL; Gerami P
Am J Dermatopathol; 2021 Apr; 43(4):243-251. PubMed ID: 33742998
[TBL] [Abstract][Full Text] [Related]
30. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
31. BRAF fusion Spitz neoplasms; clinical morphological, and genomic findings in six cases.
Kim D; Khan AU; Compres EV; Zhang B; Sunshine JC; Quan VL; Gerami P
J Cutan Pathol; 2020 Dec; 47(12):1132-1142. PubMed ID: 32776349
[TBL] [Abstract][Full Text] [Related]
32. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
33. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.
Dobre EG; Nichita L; Popp C; Zurac S; Neagu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396984
[TBL] [Abstract][Full Text] [Related]
34. Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
Costa S; Byrne M; Pissaloux D; Haddad V; Paindavoine S; Thomas L; Aubin F; Lesimple T; Grange F; Bonniaud B; Mortier L; Mateus C; Dreno B; Balme B; Vergier B; de la Fouchardiere A
Am J Surg Pathol; 2016 Mar; 40(3):368-77. PubMed ID: 26645730
[TBL] [Abstract][Full Text] [Related]
35. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
[TBL] [Abstract][Full Text] [Related]
36. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
37. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
[TBL] [Abstract][Full Text] [Related]
38. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
39. Relevance of BRAF Subcellular Localization and Its Interaction with
Beleaua MA; Jung I; Braicu C; Milutin D; Gurzu S
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769348
[TBL] [Abstract][Full Text] [Related]
40. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
